Management of Premenstrual Syndrome: Green-top Guideline No. 48

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 124, Issue 3, 2017, Pages e73-e105

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

DANAZOL; ESTRADIOL; ESTROGEN; GESTAGEN; GONADORELIN DERIVATIVE; ORAL CONTRACEPTIVE AGENT; SEROTONIN UPTAKE INHIBITOR; TIBOLONE;

ARTICLE; BONE DENSITY; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; COGNITIVE BEHAVIORAL THERAPY; DATA ANALYSIS; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DISEASE EXACERBATION; DRUG EFFICACY; DRUG RESPONSE; ENDOMETRIUM ABLATION; HORMONE SUBSTITUTION; HUMAN; HYSTERECTOMY; MEDICAL SERVICE; OVARIECTOMY; PATHOGENESIS; PATIENT REFERRAL; PREMENSTRUAL SYNDROME; PREVALENCE; PROFESSIONAL KNOWLEDGE; RISK ASSESSMENT; RISK FACTOR; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 85006380802     PISSN: 14700328     EISSN: 14710528     Source Type: Journal    
DOI: 10.1111/1471-0528.14260     Document Type: Article

References (132)

1. O'Brien S, Rapkin A, Dennerstein L, Nevatte T. Diagnosis and management of premenstrual disorders. BMJ 2011;342:d2994.
2. O'Brien PM, Bäckström T, Brown C, Dennerstein L, Endicott J, Epperson CN, et al. Towards a consensus on diagnostic criteria, measurement and trial design of the premenstrual disorders: the ISPMD Montreal consensus. Arch Womens Ment Health 2011;14:13–21.
3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV), 4th edn. Washington DC: APA; 1994.
4. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-V), 5th edn. Washington DC: APA; 2013.
5. Pearlstein T. Prevalence, impact on morbidity, and disease burden. In: O'Brien PM, Rapkin AJ, Schmidt PJ, editors. The Premenstrual Syndromes: PMS and PMDD. Boca Raton, FL, USA: CRC Press; 2007. p. 37–47.
6. Sadler C, Smith H, Hammond J, Bayly R, Borland S, Panay N, et al.; Southampton Women's Survey Study Group. Lifestyle factors, hormonal contraception, and premenstrual symptoms: the United Kingdom Southampton Women's Survey. J Womens Health (Larchmt) 2010;19:391–6.
7. Yonkers KA, O'Brien PM, Eriksson E. Premenstrual syndrome. Lancet 2008;371:1200–10.
8. Endicott J, Nee J, Harrison W. Daily Record of Severity of Problems (DRSP): reliability and validity. Arch Womens Ment Health 2006;9:41–9.
9. Steiner M, Macdougall M, Brown E. The premenstrual symptoms screening tool (PSST) for clinicians. Arch Womens Ment Health 2003;6:203–9.
10. National Association for Premenstrual Syndrome. [http://www.pms.org.uk/support/menstrualdiary]. Accessed 2016 Jun 29.
11. Ng CY, Panay N. Management of severe pre-menstrual syndrome. In: Barter J, Hampton N, editors. The Year in Gynaecology 2002. Oxford: Clinical Publishing Services; 2002. p. 181–96.
12. Girman A, Lee R, Kligler B. An integrative medicine approach to premenstrual syndrome. Am J Obstet Gynecol 2003;188 Suppl 2:S56–65.
13. Yonkers KA, Brown C, Pearlstein TB, Foegh M, Sampson-Landers C, Rapkin A. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol 2005;106:492–501.
14. Freeman EW, Kroll R, Rapkin A, Pearlstein T, Brown C, Parsey K, et al. Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder. J Womens Health Gend Based Med 2001;10:561–9.
15. Rocha Filho EA, Lima JC, Pinho Neto JS, Montarroyos U. Essential fatty acids for premenstrual syndrome and their effect on prolactin and total cholesterol levels: a randomized, double blind, placebo-controlled study. Reprod Health 2011;8:2.
16. Dante G, Facchinetti F. Herbal treatments for alleviating premenstrual symptoms: a systematic review. J Psychosom Obstet Gynaecol 2011;32:42–51.
17. Whelan AM, Jurgens TM, Naylor H. Herbs, vitamins and minerals in the treatment of premenstrual syndrome: a systematic review. Can J Clin Pharmacol 2009;16:e407–29.
18. van Die MD, Burger HG, Teede HJ, Bone KM. Vitex agnus-castus extracts for female reproductive disorders: a systematic review of clinical trials. Planta Med 2013;79:562–75.
19. Di Pierro F, Prazzoli R, Candidi C, Attolico M. [Premenstrual syndrome: controlled clinical trial with a fast acting form of a highly standardized extract of Vitex agnus castus.] G Ital Ostet Ginecol 2009;31:153–7. Italian.
20. Canning S, Waterman M, Orsi N, Ayres J, Simpson N, Dye L. The efficacy of Hypericum perforatum (St John's Wort) for the treatment of premenstrual syndrome: a randomized, double-blind, placebo-controlled trial. CNS Drugs 2010;24:207–25.
21. Hicks SM, Walker AF, Gallagher J, Middleton RW, Wright J. The significance of “nonsignificance” in randomized controlled studies: a discussion inspired by a double-blinded study on St. John's Wort (Hypericum perforatum L.) for premenstrual symptoms. J Altern Complement Med 2004;10:925–32.
22. Prior JC, Vigna Y, Alojada N. Conditioning exercise decreases premenstrual symptoms. A prospective controlled three month trial. Eur J Appl Physiol Occup Physiol 1986;55:349–55.
23. Prior JC, Vigna Y, Sciarretta D, Alojado N, Schulzer M. Conditioning exercise decreases premenstrual symptoms: a prospective, controlled 6-month trial. Fertil Steril 1987;47:402–8.
24. Steege JF, Blumenthal JA. The effects of aerobic exercise on premenstrual symptoms in middle-aged women: a preliminary study. J Psychosom Res 1993;37:127–33.
25. Stoddard JL, Dent CW, Shames L, Bernstein L. Exercise training effects on premenstrual distress and ovarian steroid hormones. Eur J Appl Physiol 2007;99:27–37.
26. Oleson T, Flocco W. Randomized controlled study of premenstrual symptoms treated with ear, hand, and foot reflexology. Obstet Gynecol 1993;82:906–11.
27. Stokes J, Mendels J. Pyridoxine and premenstrual tension. Lancet 1972;i:1177–8.
28. Abraham GE, Hargrove JT. Effect of vitamin B6 on premenstrual symptomatology in women with premenstrual tension syndromes: A double blind crossover study. Infertility 1980;3:155–65.
29. Mattes JA, Martin D. Pyridoxine in premenstrual depression. Hum Nutr Appl Nutr 1982;36:131–3.
30. Barr W. Pyridoxine supplements in the premenstrual syndrome. Practitioner 1984;228:425–7.
31. Williams MJ, Harris RI, Dean BC. Controlled trial of pyridoxine in the premenstrual syndrome. J Int Med Res 1985;13:174–9.
32. Hagen I, Nesheim BI, Tuntland T. No effect of vitamin B-6 against premenstrual tension. A controlled clinical study. Acta Obstet Gynecol Scand 1985;64:667–70.
33. Smallwood J, Ah-Kye D, Taylor I. Vitamin B6 in the treatment of pre-menstrual mastalgia. Br J Clin Pract 1986;40:532–3.
34. Kendall KE, Schnurr PP. The effects of vitamin B6 supplementation on premenstrual symptoms. Obstet Gynecol 1987;70:145–9.
35. Doll H, Brown S, Thurston A, Vessey M. Pyridoxine (vitamin B6) and the premenstrual syndrome: a randomized crossover trial. J R Coll Gen Pract 1989;39:364–8.
36. Diegoli MS, da Fonseca AM, Diegoli CA, Pinotti JA. A double-blind trial of four medications to treat severe premenstrual syndrome. Int J Gynaecol Obstet 1998;62:63–7.
37. 6 for the relief of anxiety-related premenstrual symptoms: a randomized, double-blind, crossover study. J Womens Health Gend Based Med 2000;9:131–9.
38. Kashanian M, Mazinani R, Jalalmanesh S. Pyridoxine (vitamin B6) therapy for premenstrual syndrome. Int J Gynaecol Obstet 2007;96:43–4.
39. Lauritzen C, Reuter HD, Repges R, Böhnert KJ, Schmidt U. Treatment of premenstrual tension syndrome with Vitex agnus castus controlled, double-blind study versus pyridoxine. Phytomedicine 1997;4:183–9.
40. Facchinetti F, Borella P, Sances G, Fioroni L, Nappi RE, Genazzani AR. Oral magnesium successfully relieves premenstrual mood changes. Obstet Gynecol 1991;78:177–81.
41. Walker AF, De Souza MC, Marakis G, Robinson PA, Morris AP, Bolland KM. Unexpected benefit of sorbitol placebo in Mg intervention study of premenstrual symptoms: implications for choice of placebo in RCTs. Med Hypotheses 2002;58:213–20.
42. Christie S, Walker AF, Hicks SM, Abeyasekera S. Flavonoid supplement improves leg health and reduces fluid retention in pre-menopausal women in a double-blind, placebo-controlled study. Phytomedicine 2004;11:11–7.
43. London RS, Bradley L, Chiamori NY. Effect of a nutritional supplement on premenstrual symptomatology in women with premenstrual syndrome: a double-blind longitudinal study. J Am Coll Nutr 1991;10:494–9.
44. Stewart A. Clinical and biochemical effects of nutritional supplementation on the premenstrual syndrome. J Reprod Med 1987;32:435–41.
45. ® for women, on premenstrual tension syndromes: II. Effect on symptomatology, using a double-blind, cross-over design. J Appl Nutr 1985;37:12–7.
46. Thys-Jacobs S, Ceccarelli S, Bierman A, Weisman H, Cohen MA, Alvir J. Calcium supplementation in premenstrual syndrome: a randomized crossover trial. J Gen Intern Med 1989;4:183–9.
47. Thys-Jacobs S, Starkey P, Bernstein D, Tian J; Premenstrual Syndrome Study Group. Calcium carbonate and the premenstrual syndrome: effects on premenstrual and menstrual symptoms. Am J Obstet Gynecol 1998;179:444–52.
48. Bryant M, Cassidy A, Hill C, Powell J, Talbot D, Dye L. Effect of consumption of soy isoflavones on behavioural, somatic and affective symptoms in women with premenstrual syndrome. Br J Nutr 2005;93:731–9.
49. Burke BE, Olson RD, Cusack BJ. Randomized, controlled trial of phytoestrogen in the prophylactic treatment of menstrual migraine. Biomed Pharmacother 2002;56:283–8.
50. Ma L, Lin S, Chen R, Wang X. Treatment of moderate to severe premenstrual syndrome with Vitex agnus castus (BNO 1095) in Chinese women. Gynecol Endocrinol 2010;26:612–6.
51. Schellenberg R. Treatment for the premenstrual syndrome with agnus castus fruit extract: prospective, randomised, placebo controlled study. BMJ 2001;322:134–7.
52. Zamani M, Neghab N, Torabian S. Therapeutic effect of Vitex agnus castus in patients with premenstrual syndrome. Acta Med Iran 2012;50:101–6.
53. Pakgohar M, Moradi M, Jamshidi AH, Mehran A. [Assessment of Vitex agnus-castus L. extract effect on treatment of premenstrual syndrome.] J Med Plants 2009;8:98–107. Persian.
54. He Z, Chen R, Zhou Y, Geng L, Zhang Z, Chen S, et al. Treatment for premenstrual syndrome with Vitex agnus castus: a prospective randomized, multi-center placebo controlled study in China. Maturitas 2009;63:99–103.
55. Pakgohar M, Ahmadi M, Salehi Surmaghi MH, Mehran A, Akhondzadeh SH. [Effect of Hypericum peforatum L. for treatment of premenstrual syndrome.] J Med Plants 2005;3:33–42. Persian.
56. Ghazanfarpour M, Kaviani M, Asadi N, Ghaffarpasand F, Ziyadlou S, Tabatabaee HR, et al. Hypericum perforatum for the treatment of premenstrual syndrome. Int J Gynaecol Obstet 2011;113:84–5.
57. Tamborini A, Taurelle R. [Value of standardized Ginkgo biloba extract (EGb 761) in the management of congestive symptoms of premenstrual syndrome.] Rev Fr Gynecol Obstet 1993;88:447–57. French.
58. Ozgoli G, Selselei EA, Mojab F, Majd HA. A randomized, placebo-controlled trial of Ginkgo biloba L. in treatment of premenstrual syndrome. J Altern Complement Med 2009;15:845–51.
59. Agha-Hosseini M, Kashani L, Aleyaseen A, Ghoreishi A, Rahmanpour H, Zarrinara AR, et al. Crocus sativus L. (saffron) in the treatment of premenstrual syndrome: a double-blind, randomised and placebo-controlled trial. BJOG 2008;115:515–9.
60. Puolakka J, Mäkäräinen L, Viinikka L, Ylikorkala O. Biochemical and clinical effects of treating the premenstrual syndrome with prostaglandin synthesis precursors. J Reprod Med 1985;30:149–53.
61. Khoo SK, Munro C, Battistutta D. Evening primrose oil and treatment of premenstrual syndrome. Med J Aust 1990;153:189–92.
62. Collins A, Cerin A, Coleman G, Landgren BM. Essential fatty acids in the treatment of premenstrual syndrome. Obstet Gynecol 1993;81:93–8.
63. Horrobin DF. The role of essential fatty acids and prostaglandins in the premenstrual syndrome. J Reprod Med 1983;28:465–8.
64. Guo S. Clinical study on the treatment of premenstrual syndrome by the Back-Shu and Front-Mu and network points acupuncture [Master's thesis]. Harbin: Heilongjiang University of Chinese Medicine; 2004.
65. Habek D, Habek JC, Barbir A. Using acupuncture to treat premenstrual syndrome. Arch Gynecol Obstet 2002;267:23–6.
66. Guo S, Sun Y. Comparison between acupuncture and medication in treatment of premenstrual syndrome. Shanghai J Acupunct Moxibust 2004;23:5–6.
67. Kim SC, Kim SN, Lim JA, Choi CM, Shim EK, Koo ST, et al. [Effects of acupuncture treatment on the premenstrual syndrome: controlled clinical trial.] J Korean Acupunct Mox Soc 2005;22:41–60. Korean.
68. Peng L. The Study on the Treatment of Jiaweisiaoyao Coordinate Acupuncture to Premenstrual Syndrome. Guangzhou: Guangzhou University of Chinese Medicine; 2009. p. 49.
69. Shin KR, Ha JY, Park HJ, Heitkemper M. The effect of hand acupuncture therapy and hand moxibustion therapy on premenstrual syndrome among Korean women. West J Nurs Res 2009;31:171–86.
70. Hong Y. Clinical therapeutic effect of scalp acupuncture on premenstrual tension syndrome. Zhongguo Zhen Jiu 2002;22:597–8.
71. Xu Y. Clinical study on the treatment of acupuncture of Back-Shu on premenstrual syndrome [Master's thesis in Chinese]. Harbin: Heilongjiang University of Chinese Medicine; 2006. p. 1–33.
72. Xu Y, Sun Y. Observation of therapeutic effect of point-through-point acupuncture method in the back on premenstrual syndrome. J Clin Acupunct Moxibust 2006;22:37–8.
73. Yu J. Preliminary observation based on a systematic review of efficacy and safety of acupuncture treatment for premenstrual syndrome [Master's thesis in Chinese]. Beijing: China Academy of Chinese Medical Sciences; 2006. p. 1–89.
74. Akbarzadeh M, Dehghani M, Moshfeghy Z, Emamghoreishi M, Tavakoli P, Zare N. Effect of Melissa officinalis capsule on the intensity of premenstrual syndrome symptoms in high school girl students. Nurs Midwifery Stud 2015;4:e27001.
75. Khayat S, Fanaei H, Kheirkhah M, Moghadam ZB, Kasaeian A, Javadimehr M. Curcumin attenuates severity of premenstrual syndrome symptoms: a randomized, double-blind, placebo-controlled trial. Complement Ther Med 2015;23:318–24.
76. Ataollahi M, Akbari SA, Mojab F, Alavi Majd H. The effect of wheat germ extract on premenstrual syndrome symptoms. Iran J Pharm Res 2015;14:159–66.
77. Hunter MS, Ussher JM, Browne SJ, Cariss M, Jelley R, Katz M. A randomized comparison of psychological (cognitive behavior therapy), medical (fluoxetine) and combined treatment for women with premenstrual dysphoric disorder. J Psychosom Obstet Gynaecol 2002;23:193–9.
78. Busse JW, Montori VM, Krasnik C, Patelis-Siotis I, Guyatt GH. Psychological intervention for premenstrual syndrome: a meta-analysis of randomized controlled trials. Psychother Psychosom 2009;78:6–15.
79. Graham CA, Sherwin BB. A prospective treatment study of premenstrual symptoms using a triphasic oral contraceptive. J Psychosom Res 1992;36:257–66.
80. Lopez LM, Kaptein AA, Helmerhorst FM. Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst Rev 2012;(2):CD006586.
81. Pearlstein TB, Bachmann GA, Zacur HA, Yonkers KA. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception 2005;72:414–21.
82. Marr J, Heinemann K, Kunz M, Rapkin A. Ethinyl estradiol 20 μg/drospirenone 3 mg 24/4 oral contraceptive for the treatment of functional impairment in women with premenstrual dysphoric disorder. Int J Gynaecol Obstet 2011;113:103–7.
83. Coffee AL, Kuehl TJ, Willis S, Sulak PJ. Oral contraceptives and premenstrual symptoms: comparison of a 21/7 and extended regimen. Am J Obstet Gynecol 2006;195:1311–9.
84. Coffee AL, Sulak PJ, Kuehl TJ. Long-term assessment of symptomatology and satisfaction of an extended oral contraceptive regimen. Contraception 2007;75:444–9.
85. Magos AL, Brincat M, Studd JW. Treatment of the premenstrual syndrome by subcutaneous estradiol implants and cyclical oral norethisterone: placebo controlled study. Br Med J (Clin Res Ed) 1986;292:1629–33.
86. Watson NR, Studd JW, Savvas M, Garnett T, Baber RJ. Treatment of severe premenstrual syndrome with oestradiol patches and cyclical oral norethisterone. Lancet 1989;ii:730–2.
87. Smith RN, Studd JW, Zamblera D, Holland EF. A randomised comparison over 8 months of 100 μg and 200 μg twice weekly doses of transdermal oestradiol in the treatment of severe premenstrual syndrome. Br J Obstet Gynaecol 1995;102:475–84.
88. Studd J. Treatment of premenstrual disorders by suppression of ovulation by transdermal estrogens. Menopause Int 2012;18:65–7.
89. Panay N, Rees M, Domoney C, Zakaria F, Guilford S, Studd JWW. A multicentre double-blind crossover study comparing 100mg transdermal oestradiol with placebo in the treatment of severe premenstrual syndrome. Menopause Int 2001;7 Suppl 3:19–20.
90. Panay N, Studd J. Progestogen intolerance and compliance with hormone replacement therapy in menopausal women. Hum Reprod Update 1997;3:159–71.
91. Faculty of Sexual & Reproductive Healthcare. Intrauterine Contraception. London: FSRH; 2015 [https://www.fsrh.org/documents/ceuguidanceintrauterinecontraception]. Accessed 2016 Jun 29.
92. Baker LJ, O'Brien PM. Potential strategies to avoid progestogen-induced premenstrual disorders. Menopause Int 2012;18:73–6.
93. Kroft J, Klostermann NR, Moody JR, Taerk E, Wolfman W. A novel regimen of combination transdermal estrogen and intermittent vaginally administered progesterone for relief of menopausal symptoms. Gynecol Endocrinol 2010;26:902–8.
94. Di Carlo C, Tommaselli GA, Gargano V, Savoia F, Bifulco G, Nappi C. Transdermal estradiol and oral or vaginal natural progesterone: bleeding patterns. Climacteric 2010;13:442–6.
95. Mansel RE, Wisbey JR, Hughes LE. Controlled trial of the antigonadotropin danazol in painful nodular benign breast disease. Lancet 1982;i:928–30.
96. Watts JF, Butt WR, Logan Edwards R. A clinical trial using danazol for the treatment of premenstrual tension. Br J Obstet Gynaecol 1987;94:30–4.
97. Hahn PM, Van Vugt DA, Reid RL. A randomized, placebo-controlled, crossover trial of danazol for the treatment of premenstrual syndrome. Psychoneuroendocrinology 1995;20:193–209.
98. O'Brien PM, Abukhalil IE. Randomized controlled trial of the management of premenstrual syndrome and premenstrual mastalgia using luteal phase–only danazol. Am J Obstet Gynecol 1999;180:18–23.
99. Brunskill PJ. The effects of fetal exposure to danazol. Br J Obstet Gynaecol 1992;99:212–5.
100. Wyatt KM, Dimmock PW, Ismail KM, Jones PW, O'Brien PM. The effectiveness of GnRHa with and without ‘add-back’ therapy in treating premenstrual syndrome: a meta analysis. BJOG 2004;111:585–93.
101. Farmer JE, Prentice A, Breeze A, Ahmad G, Duffy JM, Watson A, et al. Gonadotrophin-releasing hormone analogues for endometriosis: bone mineral density. Cochrane Database Syst Rev 2003;(4):CD001297.
102. Leather AT, Studd JW, Watson NR, Holland EF. The prevention of bone loss in young women treated with GnRH analogues with “add-back” estrogen therapy. Obstet Gynecol 1993;81:104–7.
103. Di Carlo C, Palomba S, Tommaselli GA, Guida M, Di Spiezio Sardo A, Nappi C. Use of leuprolide acetate plus tibolone in the treatment of severe premenstrual syndrome. Fertil Steril 2001;75:380–4.
104. Kanis JA, Johnell O, Oden A, Johansson H, De Laet C, Eisman JA, et al. Smoking and fracture risk: a meta-analysis. Osteoporos Int 2005;16:155–62.
105. Johansson H, Kanis JA, Odén A, McCloskey E, Chapurlat RD, Christiansen C, et al. A meta-analysis of the association of fracture risk and body mass index in women. J Bone Miner Res 2014;29:223–33.
106. Babatunde OO, Forsyth JJ, Gidlow CJ. A meta-analysis of brief high-impact exercises for enhancing bone health in premenopausal women. Osteoporos Int 2012;23:109–19.
107. Blake GM, Fogelman I. The role of DXA bone density scans in the diagnosis and treatment of osteoporosis. Postgrad Med J 2007;83:509–17.
108. National Institute for Health and Clinical Excellence. Osteoporosis: Assessing the Risk of Fragility Fracture. NICE clinical guideline 146. Manchester: NICE; 2012.
109. Wyatt K, Dimmock P, Jones P, Obhrai M, O'Brien S. Efficacy of progesterone and progestogens in management of premenstrual syndrome: systematic review. BMJ 2001;323:776–80.
110. Ford O, Lethaby A, Roberts H, Mol BW. Progesterone for premenstrual syndrome. Cochrane Database Syst Rev 2012;(3):CD003415.
111. Ashby CR Jr, Carr LA, Cook CL, Steptoe MM, Franks DD. Alteration of platelet serotonergic mechanisms and monoamine oxidase activity in premenstrual syndrome. Biol Psychiatry 1988;24:225–33.
112. Biegon A, Bercovitz H, Samuel D. Serotonin receptor concentration during the estrous cycle of the rat. Brain Res 1980;187:221–5.
113. 2A receptors following estrogen treatment in postmenopausal women. Am J Psychiatry 2003;160:1522–4.
114. Moses-Kolko EL, Berga SL, Greer PJ, Smith G, Cidis Meltzer C, Drevets WC. Widespread increases of cortical serotonin type 2A receptor availability after hormone therapy in euthymic postmenopausal women. Fertil Steril 2003;80:554–9.
115. Marjoribanks J, Brown J, O'Brien PM, Wyatt K. Selective serotonin reuptake inhibitors for premenstual syndrome. Cochrane Database Syst Rev 2013;(6):CD001396.
116. Cohen LS, Soares CN, Lyster A, Cassano P, Brandes M, Leblanc GA. Efficacy and tolerability of premenstrual use of venlafaxine (flexible dose) in the treatment of premenstrual dysphoric disorder. J Clin Psychopharmacol 2004;24:540–3.
117. Freeman EW, Jabara S, Sondheimer SJ, Auletto R. Citalopram in PMS patients with prior SSRI treatment failure: a preliminary study. J Womens Health Gend Based Med 2002;11:459–64.
118. Eriksson E, Ekman A, Sinclair S, Sörvik K, Ysander C, Mattson UB, et al. Escitalopram administered in the luteal phase exerts a marked and dose-dependent effect in premenstrual dysphoric disorder. J Clin Psychopharmacol 2008;28:195–202.
119. Kornstein SG, Pearlstein TB, Fayyad R, Farfel GM, Gillespie JA. Low-dose sertraline in the treatment of moderate-to-severe premenstrual syndrome: efficacy of 3 dosing strategies. J Clin Psychiatry 2006;67:1624–32.
120. Freeman EW, Rickels K, Sondheimer SJ, Polansky M, Xiao S. Continuous or intermittent dosing with sertraline for patients with severe premenstrual syndrome or premenstrual dysphoric disorder. Am J Psychiatry 2004;161:343–51.
121. Shah NR, Jones JB, Aperi J, Shemtov R, Karne A, Borenstein J. Selective serotonin reuptake inhibitors for premenstrual syndrome and premenstrual dysphoric disorder: a meta-analysis. Obstet Gynecol 2008;111:1175–82.
122. Udechuku A, Nguyen T, Hill R, Szego K. Antidepressants in pregnancy: a systematic review. Aust N Z J Psychiatry 2010;44:978–96.
123. Furu K, Kieler H, Haglund B, Engeland A, Selmer R, Stephansson O, et al. Selective serotonin reuptake inhibitors and venlafaxine in early pregnancy and risk of birth defects: population based cohort study and sibling design. BMJ 2015;350:h1798.
124. Wang M, Hammarbäck S, Lindhe BA, Bäckström T. Treatment of premenstrual syndrome by spironolactone: a double-blind, placebo-controlled study. Acta Obstet Gynecol Scand 1995;74:803–8.
125. O'Brien PM, Craven D, Selby C, Symonds EM. Treatment of premenstrual syndrome by spironolactone. Br J Obstet Gynaecol 1979;86:142–7.
126. Cronje WH, Vashisht A, Studd JW. Hysterectomy and bilateral oophorectomy for severe premenstrual syndrome. Hum Reprod 2004;19:2152–5.
127. Nappi RE, Wawra K, Schmitt S. Hypoactive sexual desire disorder in postmenopausal women. Gynecol Endocrinol 2006;22:318–23.
128. Studd J, Panay N. Hormones and depression in women. Climacteric 2004;7:338–46.
129. Leminen H, Heliövaara-Peippo S, Halmesmäki K, Teperi J, Grenman S, Kivelä A, et al. The effect of hysterectomy or levonorgestrel-releasing intrauterine system on premenstrual symptoms in women treated for menorrhagia: secondary analysis of a randomized controlled trial. Acta Obstet Gynecol Scand 2012;91:318–25.
130. Lukes AS, McBride RJ, Herring AH, Fried M, Sherwani A, Dell D. Improved premenstrual syndrome symptoms after NovaSure endometrial ablation. J Minim Invasive Gynecol 2011;18:607–11.
131. Nevatte T, O'Brien PM, Bäckström T, Brown C, Dennerstein L, Endicott J, et al.; Consensus Group of the International Society for Premenstrual Disorders. ISPMD consensus on the management of premenstrual disorders. Arch Womens Ment Health 2013;16:279–91.
132. Panay N. Treatment of premenstrual syndrome: a decision-making algorithm. Menopause Int 2012;18:90–2.